Filing Details
- Accession Number:
- 0001144204-13-033477
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-05 18:47:54
- Reporting Period:
- 2013-06-03
- Filing Date:
- 2013-06-05
- Accepted Time:
- 2013-06-05 18:47:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1087939 | Julian Baker | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1087940 | Felix Baker | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1263508 | Baker Bros Advisors Llc | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1363364 | Baker Brothers Life Sciences Lp | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1551138 | 14159, L.p. | 667 Madision Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1551139 | 667, L.p. | 667 Madison Avenue 21St Floor New York NY US 10065 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-06-03 | 56,274 | $14.08 | 1,320,595 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-03 | 461,548 | $14.08 | 16,422,130 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-03 | 11,511 | $14.08 | 401,420 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-03 | 25,368 | $14.00 | 1,345,963 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-03 | 208,063 | $14.00 | 16,630,193 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-03 | 5,189 | $14.00 | 406,609 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 4,353 | $14.50 | 1,350,316 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 35,702 | $14.50 | 16,665,895 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 890 | $14.50 | 407,499 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 56,475 | $14.45 | 1,406,791 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 463,197 | $14.45 | 17,129,092 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 11,552 | $14.45 | 419,051 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 13,566 | $14.42 | 1,420,357 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 111,266 | $14.42 | 17,240,358 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2013-06-04 | 2,775 | $14.42 | 421,826 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 26,577 | $14.46 | 1,446,934 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 217,986 | $14.46 | 17,458,344 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 5,437 | $14.46 | 427,263 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 21,080 | $14.58 | 1,468,014 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 172,893 | $14.58 | 17,631,237 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 4,312 | $14.58 | 431,575 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 18,530 | $14.55 | 1,486,544 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 151,980 | $14.55 | 17,783,217 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 3,790 | $14.55 | 435,365 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 26,577 | $14.46 | 1,513,121 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 217,986 | $14.46 | 18,001,203 | No | 4 | P | Indirect | See Footnote |
Common Stoc | Acquisiton | 2013-06-05 | 5,437 | $14.46 | 440,802 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Footnotes
- After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers Life Sciences. L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Column 5 of Table I directly held by 14159, L.P ("14159", and together with Baker Tisch, Baker Bros. Investments, Baker Bros. Investments II, 667 and Life Sciences, the "Funds"), a limited partnership of which the sole general partner is 14159 Capital L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital L.P.'s right to receive an allocation of a portion of the profits from 14159.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $13.70 to $14.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $13.70 to $14.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.36 to $14.59, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.12 to $14.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.18 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.28 to $14.60, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.29 to $14.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.37 to $14.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 667 in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by Life Sciences in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased by 14159 in multiple transactions at prices ranging from $14.30 to $14.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- The aggregate indirect beneficial ownership reported on this form is 19,955,126 shares.
- Baker Bros. Advisors, LLC (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Julian C. Baker and Felix J. Baker are principals of the Adviser. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.